Neurotech Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 164

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $550M

Neurotech General Information

Description

Developer of encapsulated cell-based therapies designed for the treatment of chronic eye diseases. The company's platform uses genetically engineered cell implants and semi-permeable capsule technology to deliver therapeutic proteins continuously, protect photoreceptors, and provide long-acting retinal treatment, helping ophthalmologists and retina practices slow the progression of vision loss in patients with macular telangiectasia type 2.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 900 Highland Corporate Drive
  • Building 1
  • Cumberland, RI 02864
  • United States
+1 (401)
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 900 Highland Corporate Drive
  • Building 1
  • Cumberland, RI 02864
  • United States
+1 (401)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 20-Oct-2026 $550M Completed Clinical Trials - Phase 3
10. Secondary Transaction - Private Completed Clinical Trials - Phase 3
9. Grant 01-Sep-2018 Completed Clinical Trials - Phase 3
8. Secondary Transaction - Private 15-Aug-2016 Completed Clinical Trials - Phase 3
7. Later Stage VC (Series F) 28-Mar-2014 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series E) 28-Jun-2013 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series D) 22-Dec-2010 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 17-Mar-2010 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B) 16-Nov-2006 $35M $48.7M Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A) 24-Nov-2003 $13.7M $13.7M Completed Clinical Trials - Phase 3
To view Neurotech’s complete valuation and funding history, request access »

Neurotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F
Series E
Series D
Series C
Series B-2 5,682,096 $0.000100 8% $1.2 $1.2 1x $1.2 3.84%
Series B-1 8,823,406 $0.000100 8% $1.03 $1.03 1x $1.03 5.96%
To view Neurotech’s complete cap table history, request access »

Neurotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of encapsulated cell-based therapies designed for the treatment of chronic eye diseases. The company's platfor
Drug Discovery
Cumberland, RI
164 As of 2026

Ann Arbor, MI
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurotech Competitors (9)

One of Neurotech’s 9 competitors is ONL Therapeutics, a Venture Capital-Backed company based in Ann Arbor, MI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Kala Bio Formerly VC-backed Arlington, MA
EyePoint Corporation Watertown, MA
Ocular Therapeutix Formerly VC-backed Bedford, MA
You’re viewing 5 of 9 competitors. Get the full list »

Neurotech Patents

Neurotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20060277220-A1 Security data redaction Active 28-Mar-2005
US-8086615-B2 Security data redaction Inactive 28-Mar-2005
AU-2001259422-A1 Immortalized lines of endothelial brain cells and therapeutic application thereof Inactive 03-May-2000
WO-2001083716-A2 Immortalized lines of endothelial brain cells and therapeutic application thereof Inactive 03-May-2000
WO-2001083716-A3 Immortalized lines of endothelial brain cells and therapeutic application thereof Inactive 03-May-2000 C12N5/069
To view Neurotech’s complete patent history, request access »

Neurotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurotech Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
Amundi Alpha Associates Fund of Funds Minority
Apax Partners PE/Buyout Minority
Atlas Venture Venture Capital Minority
Burrill & Co Merchant Banking Firm Minority
You’re viewing 5 of 21 investors. Get the full list »

Neurotech FAQs

  • When was Neurotech founded?

    Neurotech was founded in 2002.

  • Where is Neurotech headquartered?

    Neurotech is headquartered in Cumberland, RI.

  • What is the size of Neurotech?

    Neurotech has 164 total employees.

  • What industry is Neurotech in?

    Neurotech’s primary industry is Drug Discovery.

  • Is Neurotech a private or public company?

    Neurotech is a Private company.

  • What is the current valuation of Neurotech?

    The current valuation of Neurotech is .

  • What is Neurotech’s current revenue?

    The current revenue for Neurotech is .

  • How much funding has Neurotech raised over time?

    Neurotech has raised $111M.

  • Who are Neurotech’s investors?

    3i Group, Amundi Alpha Associates, Apax Partners, Atlas Venture, and Burrill & Co are 5 of 21 investors who have invested in Neurotech.

  • Who are Neurotech’s competitors?

    ONL Therapeutics, Foventa Therapeutics, Kala Bio, EyePoint, and Ocular Therapeutix are some of the 9 competitors of Neurotech.

  • When was Neurotech acquired?

    Neurotech was acquired on 20-Oct-2026.

  • Who acquired Neurotech?

    Neurotech was acquired by Alcon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process